Ipsen and Arix Bioscience agree new drug research alliance

Ipsen has announced a new drug research collaboration with Arix Bioscience focused on the development and commercialisation of innovative new therapies.

Under the terms of the agreement, Arix will provide Ipsen with access to its network of professional and scientific advisors, as well as offering opportunities to invest in Arix's new and existing businesses.

In exchange, Ipsen will contribute research, development and commercial expertise to the partnership, with both companies set to jointly identify new goals and create new businesses to aid the development of innovative therapies for patients.

Arix made investments into 13 life science companies in 2016 and 2017, with multiple milestones expected over the next 18 months. It expects to continue to expand this pipeline and provide additional funding and expertise in 2018.

David Meek, chief executive officer of Ipsen, said: "By building this relationship with Arix, we can benefit from Arix's leading networks, advisors and businesses and can support these in turn with our research and development and commercialisation capabilities and expertise."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.